Company profile
Suzhou Alphamab
China antibody-engineering biotech (mAbs, fusion proteins, bispecifics) -- private parent entity distinct from the HKEX-listed spinout Alphamab Oncology (9966.HK)
Privately held: no public share price · China
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PD-L1Monoclonal antibody | HIVNon-Small Cell Lung CancerChronic Hepatitis B | |
| Phase 2 | Factor XI/XIa (FXI/FXIa)Monoclonal antibody | Hypertension |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.